Results 201 to 210 of about 5,904 (237)

A case of Takotsubo syndrome with polymorphic ventricular tachycardia and shark fin electrocardiogram developed during hospitalization for occlusive arterial disease of the lower extremities. [PDF]

J Cardiol Cases
Fujiwara M, Ito H, Yamada H, Soeki T.
europepmc   +1 more source

Analysis and Validation of Autophagy-Related Gene Biomarkers and Immune Cell Infiltration Characteristic in Bronchopulmonary Dysplasia by Integrating Bioinformatics and Machine Learning. [PDF]

J Inflamm Res
Xiao S, Ding Y, Du C, Lv Y, Yang S, Zheng Q, Wang Z, Zheng Q, Huang M, Xiao Q, Ren Z, Bi G, Yang J.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ERECTILE RESPONSE TO TRANSURETHRAL ALPROSTADIL, PRAZOSIN AND ALPROSTADIL-PRAZOSIN COMBINATIONS

Journal of Urology, 1998
Transurethral alprostadil has been shown to be efficacious in many men with erectile dysfunction. We compared transurethral alprostadil and prazosin alone, and in combination to treat this disorder.In this double-blind, placebo controlled study the erectile responses to transurethral alprostadil, prazosin and alprostadil-prazosin combinations were ...
Neil Gesundheit, Alan H. Bennett, Wayne J.G. Hellstrom, Peter Y. Tam, Fran E. Kaiser, John E. Morley, Leslie K. Todd, Emil A. Tanagho, John C. Varady, Kerry J. Nemo, Harin Padma-Nathan, Virgil A. Place, J. Joseph Prendergast, Craig A. Peterson   +13 more
openaire   +2 more sources

Alprostadil for the treatment of impotence

Expert Opinion on Pharmacotherapy, 2013
Erectile dysfunction (ED) affects over 150 million men worldwide. Oral phosphodiesterase-5 (PDE5) inhibitors are currently used as a first-line therapy and a second-line therapy with either intracavernosal (Caverject) or intraurethral (MUSE) alprostadil is required for a few men who show poor response or intolerance to PDE5 inhibitors.This article ...
Vishwanath Hanchanale, Ian Eardley
openaire   +2 more sources

Intra-arterial Alprostadil for Nonatherosclerotic Vasculopathy [PDF]

JAMA: The Journal of the American Medical Association, 1981
A 33-year-old man with a nonatherosclerotic vasculopathy of undetermined origin had progressive occlusive disease of the lower limb vessels. The resultant severe rest pain and ischemic ulceration of his foot were inoperable and unresponsive to conventional drug therapy.
Peter N. Madras, C. J. Shamess, E. C. Keystone, D. L. Wooster   +3 more
openaire   +2 more sources

Evaluation of Inhaled Alprostadil in Hospitalized Adult Patients

Annals of Pharmacotherapy, 2021
Background: Intermittent inhaled alprostadil (iPGE1) may be a viable alternative to inhaled nitric oxide or epoprostenol for management of right ventricular failure, pulmonary hypertension (pHTN) or acute respiratory distress syndrome (ARDS). However, limited evidence exists regarding iPGE1 use in adults, ideal dosing strategies, or optimal use cases ...
Hangil Seo, Chelsea N. Lopez, Luma Succar, Kevin R. Donahue   +3 more
openaire   +2 more sources

Optimizing the therapeutic approach of transurethral alprostadil

BJU International, 2000
Objective To investigate the efficacy and safety of two different starting doses of transurethral alprostadil (250 µg and 500 µg, MUSE®, Vivus Inc., Menlo Park, CA, USA, and Astra Läkemedel AB, Södertälje, Sweden) and the need for dose titration in a general population with erectile dysfunction.
P. Ekman, Gunnar Englund, L. Sjögren, B.-E. Persson   +3 more
openaire   +3 more sources

Alprostadil: An Effective Antiplatelet Agent for Calves

Artificial Organs, 1993
Abstract:Aspirin and other nonsteroidal, antiinflammatory drugs inhibit human platelets, but their effect as an antiplatelet agent on bovine platelets is not certain. Since calves are used for cardiovascular implant research, need exists for an effective antiplatelet agent for this animal model.
Gregory L. Burns, Don B. Olsen, Ruurd L. Jaarsma, S. Fazal Mohammad   +3 more
openaire   +3 more sources

Alprostadil for erectile impotence

Drug and Therapeutics Bulletin, 1995
A preparation of alprostadil (prostaglandin E1) plus syringe and diluent (Caverject - Upjohn) has recently been licensed in the UK for the treatment of erectile impotence by injection into the corpus cavernosum. How does it compare with papaverine, which, though unlicensed for this indication, has been the mainstay of drug treatment for impotence?
openaire   +2 more sources

A Cost Analysis of Alprostadil in Liver Transplantation

PharmacoEconomics, 1996
Alprostadil (prostaglandin E1) administration to liver transplant recipients has been shown to result in a significant reduction in the duration of hospital admission for transplantation, and in the need for re-operations (other than re-transplants) and renal support.
I. Douglas McLaren, Darrell A. Campbell, Steven L. Hass, Dean G. Smith, Carl S. Remmert, Keith S. Henley   +5 more
openaire   +3 more sources